Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Precision Biosciences Inc (NQ: DTIL )

10.56 +0.72 (+7.32%)
Streaming Delayed Price Updated: 3:31 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Precision Biosciences Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Change to its Board of Directors
From Precision BioSciences, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  OnFriday, 143 stocks hit new 52-week lows. 
Via Benzinga
Precision BioSciences Earnings Perspective: Return On Capital Employed
Via Benzinga
Coinbase To $80? Plus Deutsche Bank Cuts PT On This Stock By 80%
Citigroup cut the price target on Coinbase Global, Inc. (NASDAQ: COIN) from $105 to $80. Citigroup analyst Peter Christiansen maintained a Buy rating on the stock. Coinbase shares rose 2.1% to $46.95... 
Via Benzinga
Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences's Earnings Outlook
Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Senior Leadership Organizational Changes
From Precision BioSciences, Inc.
Via Business Wire
Looking Into Precision BioSciences, Inc. - Common Stock's Return On Capital Employed
Benzinga Pro data, Precision BioSciences, Inc. - Common Stock (NASDAQ:DTIL) reported Q2 sales of $3.82 million. Earnings fell to a loss of $31.04 million, resulting in a 10.18% decrease from last... 
Via Benzinga
Precision BioSciences: Q2 Earnings Insights
  Precision BioSciences (NASDAQ:DTIL) reported its Q2 earnings results on Monday, August 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Earnings Preview: Precision BioSciences, Inc. - Common Stock
Precision BioSciences, Inc. - Common Stock (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. 
Via Benzinga
Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Precision BioSciences Announces Closing of Underwritten Offering of Common Stock
From Precision BioSciences, Inc.
Via Business Wire
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent... 
Via FinancialNewsMedia
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
Exela Technologies (XELA) Stock Soars After Securing $136 Million Contract
Exela Technologies (XELA) stock is taking off on Wednesday after gaining a new $136 million customer contract that lasts for three years. 
Via InvestorPlace
Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Results
Athira Pharma (ATHA) stock is plummeting on Wednesday following the outcome of a Phase 2 clinical trial of fosgonimeton. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.